Literature DB >> 11558582

Inactivation of rat cytochrome P450 2D enzyme by a further metabolite of 4-hydroxypropranolol, the major and active metabolite of propranolol.

S Narimatsu1, T Arai, Y Masubuchi, T Horie, M Hosokawa, K Ueno, H Kataoka, S Yamamoto, T Ishikawa, A K Cho.   

Abstract

Repetitive administration of propranolol (PL) in rats decreases the activities of cytochrome P450 (CYP) 2D enzyme(s) in hepatic microsomes. We examined the properties of 4-hydroxypropranolol (4-OH-PL) as an inactivator of rat liver microsomal CYP2D enzyme(s) using bunitrolol (BTL) 4-hydroxylation and PL 5- and 7-hydroxylations as indices of CYP2D enzyme activity. Rat microsomal BTL 4-hydroxylase activity was inhibited by the addition of 4-OH-PL to the incubation medium. The inhibition was greater after preincubation of microsomes with 4-OH-PL in the presence of NADPH than in its absence. The type of inhibition kinetics of BTL 4-hydroxylase by 4-OH-PL was changed from a competitive type to a noncompetitive type by the preincubation. The inhibition of rat liver microsomal PL 5- and 7-hydroxylases by 4-OH-PL was blocked efficiently by co-incubation with quinine, a typical inhibitor of rat CYP2D enzyme(s), or to a lesser extent by BTL. However, quinidine, a diastereomer of quinine, did not significantly protect against the enzyme inactivation. The protective capacities of the substrate and inhibitors reflected their affinities for rat CYP2D enzyme(s). BTL hydroxylase was not affected by either 1,4-naphthoquinone or 1,4-dihydroxynaphthalene which are possible metabolites of 4-OH-PL. These results provide further evidence to support the notion that PL is biotransformed by rat CYP2D enzyme(s) to 4-OH-PL, which is further oxidized to a chemically reactive metabolite in the active site. The inactivation of CYP is likely the result of covalent binding of the reactive species to an amino acid residue of the active site.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11558582     DOI: 10.1248/bpb.24.988

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  5 in total

1.  Nicotine Increases Codeine Analgesia Through the Induction of Brain CYP2D and Central Activation of Codeine to Morphine.

Authors:  Douglas M McMillan; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2015-01-29       Impact factor: 7.853

2.  First demonstration that brain CYP2D-mediated opiate metabolic activation alters analgesia in vivo.

Authors:  Kaidi Zhou; Jibran Y Khokhar; Bin Zhao; Rachel F Tyndale
Journal:  Biochem Pharmacol       Date:  2013-04-23       Impact factor: 5.858

3.  Evaluation of In Vitro Cytochrome P450 Inhibition and In Vitro Fate of Structurally Diverse N-Oxide Metabolites: Case Studies with Clozapine, Levofloxacin, Roflumilast, Voriconazole and Zopiclone.

Authors:  Poonam Giri; Sneha Naidu; Nirmal Patel; Harilal Patel; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

4.  The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes.

Authors:  Momir Mikov; Maja Đanić; Nebojša Pavlović; Bojan Stanimirov; Svetlana Goločorbin-Kon; Karmen Stankov; Hani Al-Salami
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-12       Impact factor: 2.441

5.  Centrally administered CYP2D inhibitors increase oral tramadol analgesia in rats.

Authors:  Douglas M McMillan; Ahmed A El-Sherbeni; Janielle Richards; Rachel F Tyndale
Journal:  Brain Res Bull       Date:  2020-09-11       Impact factor: 4.077

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.